Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607220810> ?p ?o ?g. }
- W2607220810 endingPage "e1312239" @default.
- W2607220810 startingPage "e1312239" @default.
- W2607220810 abstract "ABSTRACTBackground: Chondromodulin-I (CHM1) sustains malignancy in Ewing sarcoma (ES). Refractory ES carries a dismal prognosis and patients with bone marrow (BM) metastases do not survive irrespective of therapy. We assessed HLA-A*02:01/CHM1-specific allorestricted T cell receptor (TCR) wild-type and transgenic cytotoxic (CD8+) T cells against ES.Patients and Methods: Three refractory HLA-A2+ ES patients were treated with HLA-A*02:01/peptide-specific allorepertoire-derived (i.e., allorestricted) CD8+ T cells. Patient #1 received up to 4.8 × 105/kg body weight HLA-A*02:01− allorestricted donor-derived wild-type CD8+ T cells. Patient #2 received up to 8.2 × 106/kg HLA-A*02:01− donor-derived and patient #3 up to 6 × 106/kg autologous allorestricted TCR transgenic CD8+ T cells. All patients were treated with the same TCR complementary determining region 3 allorecognition sequence for CHM1 peptide 319 (CHM1319).Results: HLA-A*02:01/CHM1319-specific allorestricted CD8+ T cells showed specific in vitro lysis of..." @default.
- W2607220810 created "2017-04-28" @default.
- W2607220810 creator A5010237107 @default.
- W2607220810 creator A5017499561 @default.
- W2607220810 creator A5021490889 @default.
- W2607220810 creator A5022338226 @default.
- W2607220810 creator A5034557738 @default.
- W2607220810 creator A5040169496 @default.
- W2607220810 creator A5040347320 @default.
- W2607220810 creator A5042560332 @default.
- W2607220810 creator A5043788875 @default.
- W2607220810 creator A5045183692 @default.
- W2607220810 creator A5046148528 @default.
- W2607220810 creator A5055408774 @default.
- W2607220810 creator A5059831431 @default.
- W2607220810 creator A5062895290 @default.
- W2607220810 creator A5072801328 @default.
- W2607220810 creator A5082079118 @default.
- W2607220810 creator A5083608565 @default.
- W2607220810 creator A5083625752 @default.
- W2607220810 creator A5089684820 @default.
- W2607220810 date "2017-05-04" @default.
- W2607220810 modified "2023-10-10" @default.
- W2607220810 title "Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells" @default.
- W2607220810 cites W1607316259 @default.
- W2607220810 cites W1939904335 @default.
- W2607220810 cites W1971439809 @default.
- W2607220810 cites W1973195150 @default.
- W2607220810 cites W1990751526 @default.
- W2607220810 cites W2010442664 @default.
- W2607220810 cites W2014605710 @default.
- W2607220810 cites W2027582676 @default.
- W2607220810 cites W2058759427 @default.
- W2607220810 cites W2067839517 @default.
- W2607220810 cites W2082509164 @default.
- W2607220810 cites W2084860391 @default.
- W2607220810 cites W2112218072 @default.
- W2607220810 cites W2116365316 @default.
- W2607220810 cites W2118796952 @default.
- W2607220810 cites W2124328974 @default.
- W2607220810 cites W2124373740 @default.
- W2607220810 cites W2143626441 @default.
- W2607220810 cites W2165119413 @default.
- W2607220810 cites W2166662937 @default.
- W2607220810 cites W2201278844 @default.
- W2607220810 cites W2298217571 @default.
- W2607220810 cites W2343246646 @default.
- W2607220810 cites W2346108121 @default.
- W2607220810 cites W2400439118 @default.
- W2607220810 cites W2413602959 @default.
- W2607220810 cites W2495694263 @default.
- W2607220810 cites W2497089950 @default.
- W2607220810 cites W2534069503 @default.
- W2607220810 cites W2603711327 @default.
- W2607220810 doi "https://doi.org/10.1080/2162402x.2017.1312239" @default.
- W2607220810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5467994" @default.
- W2607220810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28638739" @default.
- W2607220810 hasPublicationYear "2017" @default.
- W2607220810 type Work @default.
- W2607220810 sameAs 2607220810 @default.
- W2607220810 citedByCount "20" @default.
- W2607220810 countsByYear W26072208102017 @default.
- W2607220810 countsByYear W26072208102018 @default.
- W2607220810 countsByYear W26072208102019 @default.
- W2607220810 countsByYear W26072208102020 @default.
- W2607220810 countsByYear W26072208102021 @default.
- W2607220810 countsByYear W26072208102022 @default.
- W2607220810 countsByYear W26072208102023 @default.
- W2607220810 crossrefType "journal-article" @default.
- W2607220810 hasAuthorship W2607220810A5010237107 @default.
- W2607220810 hasAuthorship W2607220810A5017499561 @default.
- W2607220810 hasAuthorship W2607220810A5021490889 @default.
- W2607220810 hasAuthorship W2607220810A5022338226 @default.
- W2607220810 hasAuthorship W2607220810A5034557738 @default.
- W2607220810 hasAuthorship W2607220810A5040169496 @default.
- W2607220810 hasAuthorship W2607220810A5040347320 @default.
- W2607220810 hasAuthorship W2607220810A5042560332 @default.
- W2607220810 hasAuthorship W2607220810A5043788875 @default.
- W2607220810 hasAuthorship W2607220810A5045183692 @default.
- W2607220810 hasAuthorship W2607220810A5046148528 @default.
- W2607220810 hasAuthorship W2607220810A5055408774 @default.
- W2607220810 hasAuthorship W2607220810A5059831431 @default.
- W2607220810 hasAuthorship W2607220810A5062895290 @default.
- W2607220810 hasAuthorship W2607220810A5072801328 @default.
- W2607220810 hasAuthorship W2607220810A5082079118 @default.
- W2607220810 hasAuthorship W2607220810A5083608565 @default.
- W2607220810 hasAuthorship W2607220810A5083625752 @default.
- W2607220810 hasAuthorship W2607220810A5089684820 @default.
- W2607220810 hasBestOaLocation W26072208101 @default.
- W2607220810 hasConcept C102230213 @default.
- W2607220810 hasConcept C104317684 @default.
- W2607220810 hasConcept C126322002 @default.
- W2607220810 hasConcept C147483822 @default.
- W2607220810 hasConcept C170493617 @default.
- W2607220810 hasConcept C188280979 @default.
- W2607220810 hasConcept C19317047 @default.
- W2607220810 hasConcept C203014093 @default.
- W2607220810 hasConcept C2776090121 @default.